Skip to main content

Clearside Biomedical, Inc.

CLSDDelisted Dec 8, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001539029

Clearside Biomedical, Inc. was delisted on Dec 8, 2025; its insiders filed their last Form 4 on Feb 24, 2025; 26 institutions reported holding it in 13F filings for Q3 2025, worth $2.18M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Clearside Biomedical, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Clearside Biomedical, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Clearside Biomedical, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Thorp ClayDirector176,141Feb 24, 20250
Lasezkay George MCEO466,577Jan 10, 20250
Deignan Charles A.Chief Financial Officer384,662Jan 10, 20250
Chong Ngai Hang VictorChief Medical Officer100,000Jan 10, 20250
Yerxa Benjamin RDirector17,957Jun 21, 20240
Shaffer Christy LDirector–Jun 21, 20240
Edwards Jeffrey LDirector–Jun 21, 20240
Hutson Nancy JDirector93,000Jun 21, 20240
Croarkin RichardDirector–Jun 21, 20240
Humphries William D.Director51,040Jun 21, 20240
Gibney Anthony SDirector100,000Jun 21, 20240
Whitmore Bradford T10% Owner4,495,034Feb 9, 20240
Ciulla ThomasChief Medical Officer291,890Jan 20, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 24, 2025 (view filing)Feb 24Same dayThorp ClayDirectorPPurchase+15.0K$0.92+$13.8K+9.3%176.1K after
Nov 4, 2024 (view filing)Nov 13 daysChong Ngai Hang VictorChief Medical OfficerPPurchase+36.5K$1.00+$36.5K+57.5%100.0K after
Jun 24, 2024 (view filing)Jun 24Same dayChong Ngai Hang VictorChief Medical OfficerPPurchase+23.5K$1.06+$24.9K+58.8%63.5K after
May 15, 2024 (view filing)May 15Same dayYerxa Benjamin RDirectorPPurchase+7.81K$1.31+$10.2K+77.0%18.0K after
Apr 19, 2024 (view filing)Apr 17-182 daysGibney Anthony SDirectorPPurchase+100.0K$1.30+$129.7KNew position100.0K after2 lots
Mar 20, 2024 (view filing)Mar 20Same dayChong Ngai Hang VictorCHIEF MEDICAL OFFICERPPurchase+30.0K$1.60+$48.0KNew position30.0K after
Feb 9, 2024 (view filing)Feb 72 daysWhitmore Bradford T10% OwnerPPurchase+444.4K$1.35+$600.0K+11.0%4.50M after
Feb 9, 2024 (view filing)Feb 72 daysWhitmore Bradford T10% OwnerPPurchase+444.4K$0.00$0–444.4K afterDerivative
Jan 19, 2024 (view filing)Jan 19Same dayLasezkay George MCEOSSale−18.0K$1.27−$22.9K−3.7%466.6K after
Jan 19, 2024 (view filing)Jan 19Same dayDeignan Charles A.Chief Financial OfficerSSale−12.9K$1.28−$16.5K−3.2%384.7K after
Nov 1, 2023 (view filing)Oct 30-Nov 12 daysWhitmore Bradford T10% OwnerPPurchase+135.8K$0.7346+$99.7K+3.5%4.05M after3 lots
Oct 4, 2023 (view filing)Oct 31 dayHutson Nancy JDirectorPPurchase+10.0K$0.86+$8.60K+12.0%93.0K after
Sep 25, 2023 (view filing)Sep 25Same dayThorp ClayDirectorPPurchase+10.0K$0.86+$8.60K+32.8%40.5K after
Jan 20, 2023 (view filing)Jan 20Same dayCiulla ThomasChief Medical OfficerSSale−13.7K$1.47−$20.1K−4.5%291.9K after
Jan 20, 2023 (view filing)Jan 191 dayLasezkay George MCEOSSale−20.0K$1.46−$29.2K−4.0%484.6K after
Jan 20, 2023 (view filing)Jan 191 dayDeignan Charles A.Chief Financial OfficerSSale−14.0K$1.50−$21.0K−3.7%363.5K after
Jan 11, 2023 (view filing)Jan 101 dayCiulla ThomasChief Medical OfficerSSale−2.17K$1.62−$3.52K−0.7%305.6K after
Dec 21, 2022 (view filing)Dec 21Same dayThorp ClayDirectorPPurchase+14.0K$1.02+$14.3K+84.7%30.5K after
Dec 19, 2022 (view filing)Feb 10, 2021677 daysThorp ClayDirectorSSale−32.9K$4.43−$145.6K−0.7%4.95M afterAmended
Nov 21, 2022 (view filing)Nov 174 daysHutson Nancy JDirectorPPurchase+30.0K$1.33+$39.9K+56.6%83.0K after
Jan 20, 2022 (view filing)Jan 191 dayCiulla ThomasChief Medical OfficerSSale−9.05K$2.13−$19.3K−3.0%295.3K afterFrom original
Jan 20, 2022 (view filing)Jan 191 dayDeignan Charles A.Chief Financial OfficerSSale−8.83K$2.09−$18.5K−2.5%351.4K afterFrom original
Jan 20, 2022 (view filing)Jan 191 dayLasezkay George MCEOSSale−10.8K$2.12−$22.9K−2.1%504.6K after
Jan 13, 2022 (view filing)Jan 112 daysLasezkay George MCEOSSale−5.10K$2.46−$12.5K−1.2%417.9K after
Sep 23, 2021 (view filing)Sep 212 daysCiulla ThomasChief Medical OfficerSSale−2.56K$6.40−$16.4K−1.0%255.6K after
Sep 23, 2021 (view filing)Sep 212 daysLasezkay George MCEOSSale−3.52K$6.46−$22.8K−0.8%423.0K after
Sep 23, 2021 (view filing)Sep 212 daysDeignan Charles A.Chief Financial OfficerSSale−2.80K$6.41−$17.9K−0.9%316.4K after
Sep 1, 2021 (view filing)Aug 30-Sep 12 daysWhitmore Bradford T10% OwnerSSale−420.3K$6.95−$2.92M−14.8%2.42M after3 lots
Aug 17, 2021 (view filing)Aug 161 dayHutson Nancy JDirectorPPurchase+3.00K$5.68+$17.0K+30.0%13.0K after